OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
HIGHG58

Cantourage Group SE

Drug RetailersVerified

Cantourage Group SE has a basic and diluted share count of 11,875,000 shares outstanding, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability and return metrics are not available for Cantourage Group SE, as the valuation snapshot does not include key financial ratios such as ROIC, EBITDA margins, or net profit margins. This lack of data makes it difficult to compare the company's performance against industry benchmarks or cohort medians. The company's revenue concentration and geographic exposure are not disclosed in the available data. Without segment or geographic breakdowns, it is unclear whether Cantourage Group SE is exposed to specific regional or product-line risks that could impact its financial stability. Growth trajectory is also unclear, as the outlook section does not provide numeric deltas or revenue history. Analysts have assigned a mean price target of 9.00 EUR, with a median of 9.00 EUR, suggesting a neutral to slightly bullish sentiment. The mean recommendation of 1.50 (on a 1-5 scale) indicates a generally positive outlook, with one strong-buy and one buy recommendation. Risk factors include the inability to assess liquidity risk, which could pose a challenge if the company faces unexpected cash flow pressures. The dilution risk is currently low, but this could change if the company issues additional shares in the future. No adjustments have been applied to the valuation metrics, and no specific risk factors are disclosed in the available data. Recent events, such as filings or transcripts, are not included in the available data. Analysts have provided price targets and recommendations, but no recent corporate actions or strategic developments are disclosed.

30-day price · HIGHG+1.18 (+24.8%)
Low$4.29High$6.40Close$5.94As of17 May, 00:00 UTC
Profile
CompanyCantourage Group SE
TickerHIGHG.DE
SectorConsumer Non-Cyclicals
BusinessFood & Drug Retailing
Industry groupFood & Drug Retailing
IndustryDrug Retailers
AI analysis

Business. Cantourage Group SE operates in the drug retailing industry, providing pharmaceutical and healthcare products to consumers.

Classification. Cantourage Group SE is classified under the Consumer Non-Cyclicals economic sector, Food & Drug Retailing business sector, and Drug Retailers industry with a confidence level of 0.92.

Cantourage Group SE has a basic and diluted share count of 11,875,000 shares outstanding, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability and return metrics are not available for Cantourage Group SE, as the valuation snapshot does not include key financial ratios such as ROIC, EBITDA margins, or net profit margins. This lack of data makes it difficult to compare the company's performance against industry benchmarks or cohort medians. The company's revenue concentration and geographic exposure are not disclosed in the available data. Without segment or geographic breakdowns, it is unclear whether Cantourage Group SE is exposed to specific regional or product-line risks that could impact its financial stability. Growth trajectory is also unclear, as the outlook section does not provide numeric deltas or revenue history. Analysts have assigned a mean price target of 9.00 EUR, with a median of 9.00 EUR, suggesting a neutral to slightly bullish sentiment. The mean recommendation of 1.50 (on a 1-5 scale) indicates a generally positive outlook, with one strong-buy and one buy recommendation. Risk factors include the inability to assess liquidity risk, which could pose a challenge if the company faces unexpected cash flow pressures. The dilution risk is currently low, but this could change if the company issues additional shares in the future. No adjustments have been applied to the valuation metrics, and no specific risk factors are disclosed in the available data. Recent events, such as filings or transcripts, are not included in the available data. Analysts have provided price targets and recommendations, but no recent corporate actions or strategic developments are disclosed.
Key takeaways
  • Cantourage Group SE operates in the drug retailing industry with a focus on pharmaceutical and healthcare products.
  • The company has no immediate dilution pressure, with basic and diluted shares outstanding being equal.
  • Analysts have assigned a neutral to slightly bullish outlook, with a mean price target of 9.00 EUR.
  • Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language.
  • Profitability and return metrics are not available, making it difficult to compare the company against industry benchmarks.
  • Revenue concentration and geographic exposure are not disclosed, limiting visibility into potential regional or product-line risks.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyEUR
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4
FY-3
FY-2$603.3k$28.7k$9.0k
FY-1$1.7M$78.0k$38.7k
FY0$2.2M$117.6k$79.3k
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4
FY-3
FY-2$44.8M$44.2M
FY-1$45.1M$44.3M
FY0$46.1M$44.3M
PeriodOCFCapExFCFSBC
FY-4
FY-3
FY-2
FY-1
FY0
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6$6.1M
FQ-5$10.9M
FQ-4$13.2M
FQ-3
FQ-2$25.6M
FQ-1
FQ0$20.1M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5$45.5M
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Food & Drug Retailing · cohort 184 companies
MetricHIGHGActivity
Op margin3.1% medp25 1.2% · p75 6.8%
Net margin2.0% medp25 0.7% · p75 4.1%
Gross margin26.1% medp25 17.2% · p75 32.0%
CapEx / revenue-2.5% medp25 -4.6% · p75 -1.4%
Debt / equity56.0% medp25 16.8% · p75 121.1%
Observations
IR observations
Mean price target9.00 EUR
Median price target9.00 EUR
High price target10.00 EUR
Low price target8.00 EUR
Mean recommendation1.50 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.30 EUR
Last actual EPS0.10 EUR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 06:43 UTC#ae18cbcc
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 03:07 UTCJob: 4cada942